CMA
SRPT icon

Cedar Mountain Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Cedar Mountain Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$431 Hold
24
– – ﹤0.01% 1066
2026
Q1 		$522 Sell
24
-8
-25% -$155 ﹤0.01% 1006
2025
Q4 		$689 Buy
32
+8
+33% +$169 ﹤0.01% 566
2025
Q3 		$462 Buy
+24
New +$428 ﹤0.01% 612

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Cedar Mountain Advisors's SRPT Position: Q2 2026 in Review

Cedar Mountain Advisors held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 24 shares worth $431. The position accounts for ﹤0.01% of the portfolio, ranked #1066.

Cedar Mountain Advisors first reported a position in SRPT in Q3 2025 and has held it in 4 quarters since. The position peaked at $689 in Q4 2025. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Cedar Mountain Advisors held 24 shares of Sarepta Therapeutics worth $431 as of Q2 2026.
  • Cedar Mountain Advisors left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #1066 holding.
  • Cedar Mountain Advisors first reported a position in Sarepta Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Cedar Mountain Advisors's Sarepta Therapeutics position peaked at $689 in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.